Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021)
Describes the approaches taken at the federal, state, and local/institutional levels to ensure an effective, equitable, and fair allocation of COVID-19 monoclonal antibody (mAbs) therapies. Highlights challenges in reaching underserved patients, and discusses access and equity considerations for mAbs treatment.
National Academies of Sciences, Engineering, and Medicine
Access · Health disparities · Specialty care